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Abstract
 
C57BL/6 mice genetically deficient in interleukin 15 (IL-15
 
2
 
/
 
2
 
 mice) were generated by gene
targeting. IL-15
 
2
 
/
 
2
 
 mice displayed marked reductions in numbers of thymic and peripheral
natural killer (NK) T cells, memory phenotype CD8
 
1
 
 T cells, and distinct subpopulations of
intestinal intraepithelial lymphocytes (IELs). The reduction but not absence of these popula-
tions in IL-15
 
2
 
/
 
2
 
 mice likely reflects an important role for IL-15 for expansion and/or survival
of these cells. IL-15
 
2
 
/
 
2
 
 mice lacked NK cells, as assessed by both immunophenotyping and
functional criteria, indicating an obligate role for IL-15 in the development and functional
maturation of NK cells. Specific defects associated with IL-15 deficiency were reversed by in
vivo administration of exogenous IL-15. Despite their immunological defects, IL-15
 
2
 
/
 
2
 
 mice
remained healthy when maintained under specific pathogen-free conditions. However, IL-
15
 
2
 
/
 
2
 
 mice are likely to have compromised host defense responses to various pathogens, as
they were unable to mount a protective response to challenge with vaccinia virus. These data
reveal critical roles for IL-15 in the development of specific lymphoid lineages. Moreover, the
ability to rescue lymphoid defects in IL-15
 
2
 
/
 
2
 
 mice by IL-15 administration represents a pow-
erful means by which to further elucidate the biological roles of this cytokine.
Key words: interleukin 15 • knockout mice • natural killer cells • CD8
 
1
 
 T lymphocytes • 
immunologic memory
 
Introduction
 
The cytokine IL-15 was discovered as a result of its “IL-2–
like” stimulatory activity on T cells (1, 2). The similar in
vitro activities of IL-2 and IL-15 stem from shared use of
common receptor signaling subunits. IL-15 and IL-2 both
interact with receptor complexes that contain the common
gamma (
 
g
 
c) and IL-2R
 
b
 
 chains. The 
 
g
 
c subunit is also
used for signaling by IL-4, IL-7, and IL-9 (3), whereas the
IL-2R
 
b
 
 subunit is used for signaling only by IL-2 and IL-
15 (4, 5). The ability of a cell to respond to IL-2 or IL-15
can also be controlled by the presence or absence of specific
receptor subunits for IL-2 or IL-15. These distinct (non-
shared) receptors, known as IL-2R
 
a
 
 and IL-15R
 
a
 
, respec-
tively, do not appear to be involved in signaling but are re-
 
quired for high-affinity binding of these cytokines.
 
 
 
Thus,
despite the fact that IL-2 and IL-15 share receptor subunits
used for signaling, differential expression of the IL-2R
 
a
 
 or
IL-15R
 
a
 
 receptor subunits allows the two cytokines to exert
qualitatively and/or quantitatively differential effects on sev-
eral cell types. In addition, IL-2 and IL-15 are produced by
different cells and in different tissues. Thus, the in vivo re-
sponses to IL-2 and IL-15 are likely to be temporally and
 
physically compartmentalized
 
 
 
(for a review, see reference 6).
Studies of mice carrying induced mutations within the
IL-2/IL-15 system provide definitive evidence that IL-2
and IL-15 have unique roles in vivo (7–12). Mice lacking
IL-2, IL-2R
 
a
 
, or IL-2R
 
b
 
 develop an autoimmune disor-
der. However, IL-2R
 
b
 
2
 
/
 
2
 
 mice have additional defects
that are not observed in mice lacking IL-2 or IL-2R
 
a
 
.
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IL-15–deficient Mice
 
These additional defects include an absence of functional
NK cells and dramatic decreases in numbers of NK T cells
and intestinal intraepithelial lymphocytes (IELs)
 
1
 
 that are
believed to develop extrathymically. The differences in the
phenotypes of mice lacking IL-2, IL-2R
 
a
 
, or IL-2R
 
b
 
 led
to the speculation that IL-2 plays a primary role in main-
taining homeostasis of thymus-derived T cells, whereas IL-
15 promotes extrathymic development and survival of T
cells and NK cells (for a review, see reference 13). More
recent studies in normal mice indicate that IL-15 is a selec-
tive growth factor for memory CD8
 
1
 
, but not CD4
 
1
 
, T
cells (14). Other studies implicate IL-15 as an anabolic fac-
tor for muscle cells (15), a differentiation factor for osteo-
clast progenitors (16), a growth factor for mast cells and in-
testinal epithelial cells (17, 18), and a general inhibitor of
apoptosis in T cells, B cells, and fibroblasts (19).
To further explore the role of IL-15 in vivo, we gener-
ated C57BL/6 mice that are genetically deficient in IL-15.
Gross histological analysis of IL-15
 
2
 
/
 
2
 
 mice revealed no
evidence of increased cellular apoptosis or generalized de-
fects in mast cells, muscle, or bone. However, the pheno-
types of mice lacking either IL-15 (described here) or IL-
15R
 
a
 
 (20) confirm a critical role for IL-15 in regulating
the development and/or expansion of NK cells, NK T
cells, and distinct IEL populations. In addition, both of
these strains of mice reveal a role for IL-15 in the mainte-
nance of the memory phenotype CD8
 
1
 
 T cell population.
IL-15
 
2
 
/
 
2
 
 mice should prove useful for studying the roles of
IL-15 in infectious disease, antitumor immunity, autoim-
mune responses, and inflammation. 
 
Materials and Methods
 
Mice.
 
C57BL/6 mice genetically deficient in IL-15 were
generated by homologous recombination in embryonic stem
(ES) cells. The structure of the murine IL-15 genomic locus has
been described (21). A gene targeting vector was constructed in
which a 7.5-kb SpeI-EcoRV fragment containing IL-15 exons
3–5, encoding amino acids 1–65 of the primary translation prod-
uct, was replaced with a PGK-neo cassette. A thymidine kinase
cassette (MC-TK) was inserted into the 5
 
9
 
 end of the vector.
C57BL/6-derived ES cells were electroporated with the IL-15
targeting vector and selected in G418 and ganciclovir as de-
scribed (22). ES cell clones carrying a targeted IL-15 gene were
identified by a combination of PCR and genomic Southern blot
analyses and were injected into BALB/c blastocysts. Resulting
male chimeras were bred to C57BL/6 females. The offspring
were analyzed for germline transmission of the mutant IL-15 al-
lele by PCR and genomic Southern blot analyses. Mice het-
erozygous for the IL-15 mutation (IL-15
 
1
 
/
 
2
 
) were intercrossed
to generate IL-15–deficient (IL-15
 
2
 
/
 
2
 
) mice.
The IL-15
 
2
 
/
 
2
 
 mice used throughout these studies were bred
at Immunex and maintained on a C57BL/6 genetic background.
All mice were housed under specific pathogen-free conditions
and were used between 9 and 20 wk of age. Age- and sex-
matched littermates (IL-15
 
1
 
/
 
1
 
 or IL-15
 
1
 
/
 
2
 
) or C57BL/6 mice
 
(Taconic Farms, Inc.) were used as controls as indicated. Initial
studies revealed no apparent difference between IL-15
 
1
 
/
 
1
 
 and
IL-15
 
1
 
/
 
2
 
 mice in cellularity of their secondary lymphoid tissues,
phenotype of spleen or LN cells, or splenic NK cell responses.
 
Blood and Serum Analyses.
 
Peripheral blood was harvested by
cardiac puncture, and blood smears were prepared. Complete
blood counts and serum chemistry analyses were conducted by
Phoenix Laboratory for Veterinarians (Everett, WA) using a
CellDyne 3500 blood analyzer and a Hitachi chemistry analyzer.
Basal levels of serum IgA, IgG, and IgM were determined by
isotype-specific ELISA as described (23).
 
Histological Analyses.
 
Mice were killed by exposure to CO
 
2
 
and weighed. A midline incision was made through the skin but
not into the abdominal wall, and 8 ml of sterile HBSS was in-
jected into the peritoneal cavity. The abdomen was gently mas-
saged, the fluid was extracted, and the cells were counted. To
evaluate mast cells, quadruplicate 100 
 
m
 
l aliquots of fluid were
diluted to 10
 
6
 
 cells/ml and centrifuged onto slides at 500 rpm for
5 min using a Shandon Cytospin
 
®
 
 II. All tissues were examined
grossly, and 37 tissues representing all major tissues of all organ
systems (skin and special senses, nervous, respiratory, digestive,
urogenital, endocrine, lymphoid, hematopoietic, and muscu-
loskeletal systems) were collected for histopathology. Tissues
were fixed in 10% neutral buffered formalin, processed and em-
bedded in paraffin, sectioned at 4 
 
m
 
m, and stained with hema-
toxylin and eosin. Body weight and selected absolute organ
weights were determined, and relative organ to body weight ra-
tios were calculated for spleen, thymus, and LNs.
 
Immunohistochemistry.
 
Spleen, inguinal and mesenteric LNs,
and thymus were quick-frozen in 2-methyl butane cooled with dry
ice. A panel of anti–mouse immunophenotypic markers for T cells,
B cells, macrophages, follicular dendritic cells, and germinal centers
were applied to 5-
 
m
 
m cryosections cut onto charged slides. The
reagents and protocols used are described in detail elsewhere (24).
 
Cell Preparation.
 
Single cell suspensions of
 
 
 
liver,
 
 
 
thymus,
spleen, and LN were prepared by gently pressing the tissues
through fine nylon or wire mesh screens. Erythrocytes were de-
pleted from spleen cell suspensions by hypotonic lysis. Intrahe-
patic mononuclear cells were separated from hepatocytes by
density centrifugation over Lympholyte M (Cedarlane) as de-
scribed (12). IELs were obtained from the small intestine and
isolated on discontinuous Percoll (Pharmacia Fine Chemicals)
gradients as described (25).
 
Antibodies and Flow Cytometry.
 
Expression of cell surface
markers was analyzed by standard two or three-color flow cytome-
try on FACScalibur™ and FACScan™ II instruments (Becton
Dickinson) and with CELLQuest™ software (Becton Dickinson).
FITC-, PE-, and biotin-conjugated mAbs and isotype-matched
controls were purchased from PharMingen. Secondary reagents to
detect binding of biotinylated mAb included streptavidin-allophy-
cocyanin (Molecular Probes), streptavidin-RED670 (GIBCO BRL),
and streptavidin-CyChrome (PharMingen).
 
In Vivo Treatment with Polyinosilic-Polycytidylic Acid or IL-15.
 
Mice were injected intraperitoneally with 0.2 ml pyrogen-free
PBS or PBS containing either polyinosilic-polycytidylic acid
(polyI:C) or human IL-15. PolyI:C-treated mice received a sin-
gle injection of 100 
 
m
 
g polyI:C (Sigma Chemical Co.). IL-15–
treated mice received 10 
 
m
 
g human IL-15 once daily for 7 d.
Chinese hamster ovary (CHO)-derived human rIL-15 was pro-
duced and purified at Immunex. Endotoxin levels were 
 
,
 
3.7
ng/mg of protein. The IL-15 for injection was prepared daily
from a concentrated stock solution. Spleens and/or LNs were
harvested 24 h after the last injection of PBS, polyI:C, or IL-15.
 
1
 
Abbreviations used in this paper:
 
 ES, embryonic stem; IEL, intestinal in-
traepithelial lymphocyte; polyI:C, polyinosilic-polycytidylic acid. 
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Analysis of NK Cell Function.
 
A chromium release assay was
used to assess the cytolytic function of splenocytes from naive or
treated mice. RBC-free splenocytes from individual mice were
used as effector cells and incubated overnight in 96-well flat-bot-
tomed plates in the presence of 5 
 
3
 
 10
 
3
 
 
 
51
 
Cr-labeled YAC-1 or
P815 target cell lines. There were four replicates per sample.
Cell-free supernatants were harvested using a Skatron harvester.
Spontaneous release (from targets incubated without effector
cells) and maximum release (from targets incubated in the pres-
ence of 1% NP-40) were also determined. The percentage of
specific lysis was calculated as: (experimental release 
 
2
 
 spontane-
ous release/maximum release 
 
2
 
 spontaneous release) 
 
3
 
 100.
 
Viral Infections.
 
The neurotropic wild-type WR strain of vac-
cinia virus (26) was prepared and titered on CV-1 cells using
standard techniques (27). Virus stocks were dispersed by sonica-
tion and diluted in endotoxin-free saline. 8-wk-old female mice
were infected intravenously with 10
 
6
 
 PFU of virus. Mice were
observed daily for signs of morbidity and mortality.
 
Results and Discussion
 
Generation and Gross Characterization of IL-15
 
2
 
/
 
2
 
 Mice.
 
Mice genetically deficient in IL-15 were generated by ho-
mologous recombination in ES cells using the construct
depicted in Fig. 1 A. Correct targeting of the IL-15 locus
was confirmed by genomic Southern blot analysis (Fig. 1
B). Although reagents for detecting murine IL-15 protein
are not available, the IL-15 mutation is expected to repre-
sent a null mutation, as it deletes the initiation codon, the
leader sequence, and the first 17 amino acids of the mature
protein. IL-15
 
2
 
/
 
2
 
 mice were generated from IL-15
 
1
 
/
 
2
 
 in-
tercrosses at the expected Mendelian frequency, did not
display any gross phenotypic anomalies, and had normal life
spans in a specific pathogen-free facility (data not shown).
 
Serological and Histological Characterization of IL-15
 
2
 
/
 
2
 
Mice.
 
All hematological and clinical chemistry values (
 
n
 
 5
 
12/group), absolute and relative body and organ weights
(n 5 18/group), abdominal cavity cytology, tissue morphol-
ogy, and immunophenotyping (n 5 3/group) were within
normal ranges for this strain of mouse in our laboratory
(data not shown). None of the IL-152/2 mice exhibited
any evidence of autoimmune disease, inflammatory bowel
disease, or any alterations in resident tissue leukocytes in-
cluding mast cells. Basal levels of serum IgA, IgG, and IgM
(n 5 14/group) were determined in mice up to 19 wk of
age and were within normal ranges in both IL-152/2 and
their littermate (IL-151/1 and IL-151/2) controls (data not
shown).
Thymic, Splenic, and LN Weight and Cellularity. Within
the course of these studies, we noted no consistent or
marked difference in the size or the cellularity of the
spleens, thymi, or peripheral LNs between small groups of
age- and sex-matched IL-152/2 and littermate control (ei-
ther IL-151/1 or IL-151/2) mice. To compare the groups
in a quantitative fashion, the lymphoid organs were re-
moved and weighed from a cohort of age-matched male
mice (n 5 17–18/group). There were no significant differ-
ences in the average absolute weights or organ to body
weight ratios of the spleens or thymi between IL-152/2
and their heterozygote littermate controls (Fig. 2 A, and
data not shown). However, the average absolute weight
and organ to body weight ratio of the peripheral LNs from
IL-152/2 mice were significantly lower than those of the
controls (Fig. 2 B, and data not shown). To compare cellu-
larity of these organs, data were pooled from numerous ex-
periments. Although groups of mice were age and sex
matched within each experiment, the pooled data samples
were derived from both male and female mice between 9
and 20 wk of age (Fig. 2, C and D). The pooled data re-
vealed a significant decrease in the average cellularity of the
peripheral LNs, but not the spleen or thymi, between IL-
152/2 mice and the controls.
IL-152/2 Mice Have Normal Numbers of Conventional Thy-
mic T Cells but Reduced Numbers of Thymic and Peripheral NK
T Cells. The relative proportions and absolute numbers
of double positive CD41CD81 immature thymocytes and
single positive CD41 or CD81 mature thymocytes were
similar in control and IL-152/2 mice (Fig. 3 A, and data
not shown). Thus, conventional thymic T cell develop-
ment appeared normal in IL-152/2 mice. In contrast, the
relative proportion and absolute numbers of thymic NK T
cells were significantly reduced in IL-152/2 mice compared
with controls (Fig. 3, B and C). Decreases in the relative
proportions and absolute numbers of NK T cells were also
observed in the spleen and liver of IL-152/2 mice (Fig. 3
B, and data not shown).
NK T cells, which express NK cell markers as well as
markers expressed on activated T cells, display a restricted
TCR repertoire characterized by invariant usage of Va14
and preferential usage of Vb8, V8b2, and Vb7 (for a re-
view, see reference 28). NK T cells are present in normal
Figure 1. Generation of IL-152/2
mice. (A) A gene targeting vector
was constructed in which a 7.5-kb
SpeI-EcoRV fragment containing
IL-15 exons 3–5, encoding amino
acids 1–65 of the primary translation
product, was replaced with a PGK-
neo cassette. A thymidine kinase cas-
sette (MC-TK) was inserted into the
59 end of the vector. C57BL/6-
derived ES cells were electroporated
with the IL-15 targeting vector and
selected in G418 and ganciclovir. (B)
ES cell clones carrying a targeted IL-
15 gene were identified by a combi-
nation of PCR and genomic South-
ern blot analyses and injected into
BALB/c blastocysts. Resulting male
chimeras were bred to C57BL/6 females, and offspring were analyzed for
germline transmission of the mutant IL-15 allele by PCR and genomic
Southern blot analyses.774 IL-15–deficient Mice
Figure 2. Lymphoid organ weights and cellular-
ity. Average values are indicated by the horizontal
lines. Significant differences in organ weights or
cellularity between groups are indicated with aster-
isks. (A) Weights of individual spleens or thymi
from 10–12.5-wk-old male IL-151/2 or IL-152/2
mice (n 5 17–18/group). (B) Total weight of six
peripheral LNs (two each of proper axillary, acces-
sory axillary, and inguinal) from individual 10–
12.5-wk-old male IL-151/2 or IL-152/2 mice (n 5
17–18/group). *P , 0.05 (Student’s t test). (C and
D) Cellularity data were collected in multiple ex-
periments, each of which used age- and sex-
matched mice. The values shown are from both
male and female mice between 9 and 20 wk of age.
Control mice included IL-151/2 littermates (used
in the majority of cases), IL-151/1 littermates, and
C57BL/6 mice. The average number of cells per
LN was calculated from the combined cellularity of
the six LNs described above. **P , 0.005 (mixed
models analysis of variance).
Figure 3. IL-152/2 mice have normal
numbers of conventional T cells but re-
duced numbers of thymic NK T cells. (A)
Thymocytes from individual male IL-
151/2 (left) or IL-152/2 (right) littermates
were analyzed for expression of CD4 and
CD8 (n 5 2/group; 12–13 wk of age).
The numbers shown represent the per-
centages of cells within each quadrant. The
thymic cellularity was similar in both
groups. The results shown are representa-
tive of three experiments. (B) NK T cell
populations of thymocytes (top), intrahe-
patic mononuclear cells (middle), and sple-
nocytes (bottom) from individual C57BL/6
or IL-152/2 mice. Live gating of the
HSAlowCD8low thymocyte population was
used to acquire data on CD44hiNK1.11 or
CD44hiTCR Vb81 thymocytes. Simi-
larly, live gating of B220null splenocytes was
used to acquire data on NK1.11TCR-b1
splenic NK T cells. The numbers shown
represent the percentage of cells with an
NK T cell phenotype. (C) Absolute num-
bers of thymic NK T populations in con-
trol and IL-152/2 mice. The numbers
shown represent the mean absolute num-
ber 6 SEM of thymic NK T cell popula-
tions from C57BL/6 or IL-152/2 mice
(n 5 3/group). NK T cell numbers were
calculated from the percentages of HSAlow
CD8low thymocytes that were Ly6Chi
NK1.11 or CD44hi and NK1.11, TCR-
a/b1, or Vb8.1,8.21. The results shown
are representative of two experiments.775 Kennedy et al.
numbers in IL-22/2 mice (11, 12). In contrast, NK T cells
are present, but dramatically reduced in number, in mice
lacking either IL-2Rb, IL-15Ra (11, 20), or IL-15 (Fig. 3,
B and C). The lower number of NK T cells in the IL-152/2
thymus was not likely due to a defect in selection, as the NK
T cells that were present exhibited the skewed Vb repertoire
expected of such cells (Fig. 3 C). Additionally, IL-152/2 thy-
mocytes exhibited normal expression and function of CD1d
(data not shown), which is the antigen-presenting molecule
that positively selects NK T cells (29–31). This observation
provides additional evidence that the basic elements required
for NK T cell selection remain intact in IL-15–deficient
mice. The observation that the NK T cells present in IL-
152/2 mice appear to have undergone a normal selection
process suggests that IL-15 is not obligatory for NK T cell
differentiation but is important for expansion/survival or
functional maturation of committed NK T cells.
IL-15 Deficiency Affects Selected IEL Subpopulations. IEL
subsets were examined to determine whether IL-15 is re-
quired for development or expansion of specific subsets of
IELs. In normal mice, the IEL compartment consists of
heterogenous populations of TCR-a/b1 and TCR-g/d1
T cells. The development or maturation of certain IEL
subsets requires an intact thymus or factors that are pro-
duced by thymic-dependent T cell populations. Most
“thymic-dependent” populations of IELs express Thy1 and
are TCR-a/b1CD8ab1 or TCR-a/b1CD41. In con-
trast, most of the IELs that are thought to mature extrathy-
mically (possibly within the gut epithelium itself) are
Thy12 and bear TCR-a/b or TCR-g/d in conjunction
with CD8aa (32, 33).
IELs were isolated from individual C57BL/6 or IL-152/2
mice, and cell yields were determined. Once isolated, the
IEL populations from individual mice were pooled and an-
alyzed by three-color flow cytometry for expression of var-
ious cell surface markers. The absolute number of CD31
IELs isolated from IL-152/2 mice was estimated to be ap-
proximately twofold lower than that of control mice.
Within the CD31 populations, the ratio of a/b to g/d
IELs was z1:1 in control and 2:1 in IL-152/2 mice (data
not shown). Thy12 IELs, which made up z50% of IEL
populations in control mice (Fig. 4, A and C), accounted
for ,5% of the total IELs in IL-152/2 mice (Fig. 4, B and
D). Within gated populations of TCR-a/b1 IELs, there
were increases in the relative proportions of CD41CD82
and CD41CD81 IELs in IL-152/2 mice compared with
the controls (Fig. 4, E and F). However, as the yield of
CD31 IELs from IL-152/2 mice was approximately two-
fold lower than that of control mice, the changes in the rel-
ative proportions of these IEL populations likely arise solely
from a decrease in the absolute number of TCR-a/b1
CD42CD81 IELs in IL-152/2 mice compared with con-
trols. The decrease in the TCR-a/b1CD42CD81 IEL
population in IL-152/2 mice resulted from a selective de-
crease in the subset of IELs that express the CD8aa ho-
modimer (Fig. 4, G and H). Thus, IL-152/2 mice have a
dramatic reduction in the specific IEL populations that are
thought to arise or mature independently of the thymus.
Abnormal IEL profiles have also been observed in IL-
2Rb2/2 and IL-15Ra2/2 mice (10, 20). It has been sug-
gested that the abnormal IEL profile in IL-2Rb2/2 mice
might be due to defects in activation-induced cell death
that promote the preferential outgrowth and accumulation
of thymic-dependent IEL populations within the gut epi-
thelia, rather than due to a decrease in expansion or survival
of thymic-independent IEL populations (34). However, the
decreases in the relative proportions of Thy12 IELs and
TCR-a/b1CD8aa1 IEL populations in IL-152/2 mice
(Fig. 4) were very similar to those observed in IL-2Rb2/2
Figure 4. IL-152/2 mice have a deficiency in selective populations of
IELs. IELs were isolated from individual 8-wk-old female C57BL/6 or
IL-152/2 mice (n 5 3/group). The isolated IELs were pooled after the
individual cell yields were determined for each mouse. The pooled sam-
ples were incubated with the indicated mAb and analyzed using three-
color flow cytometry. Viable lymphocytes were gated on the basis of for-
ward and side scatter. A total of 200,000 events was collected for each
sample. (A–D) IELs were incubated with mAb specific for CD3, Thy1.2,
and TCR-a/b or TCR-g/d. Gated populations of CD31 IELs were an-
alyzed for expression of Thy1.2 and TCR-a/b (A and B) or Thy1.2 and
TCR-g/d (C and D). The numbers shown represent the percentage of
CD31 IELs within each quadrant. (E–H) IELs were incubated with mAb
specific for TCR-a/b, CD8a, and CD4 or CD8b. Gated populations of
TCR-a/b1 IELs were analyzed for expression of CD4 and CD8a (E and
F) or CD8b and CD8a (G and H). The numbers shown represent the
percentage of TCR-a/b1 IELs within each quadrant.776 IL-15–deficient Mice
mice (10). In addition, the absolute number of IELs isolated
from IL-15Ra2/2 mice is reduced approximately twofold
and the relative proportions of CD8aa1 and TCR-g/d1
IELs are reduced three- to fourfold compared with controls
(20). The selective reduction of these particular subsets of
IELs in IL-152/2 and IL-15Ra2/2 mice, neither of which
appear to have defects in activation-induced cell death,
points to a critical role for IL-15 in the development or
maintenance of IEL populations that mature extrathymically.
IL-152/2 Mice Have a Reversible NK Cell Defect. Flow
cytometric analysis of splenocytes from naive IL-152/2 mice
revealed that they had a severe reduction or absence of cells
with an NK (NK1.11CD32) phenotype (data not shown).
To determine whether IL-152/2 mice lacked functional
splenic NK cells, their splenocytes were tested for cytolytic
activity against NK-sensitive targets. Splenocytes from PBS-
treated control mice exhibited low to weak NK activity,
whereas splenocytes from polyI:C-treated control mice ex-
hibited strong NK activity (Fig. 5 A). In contrast, splenocytes
from IL-152/2 mice exhibited no demonstrable spontaneous
or polyI:C-inducible NK activity.
Treatment of normal mice with IL-15 induces strong
splenic NK cell responses and increases the relative propor-
tion and absolute number of splenic NK cells (35, 36). To
determine whether the functional NK cell defect in IL-152/2
mice was reversible, adult mice were treated with human
IL-15 for 7 d. Splenocytes were harvested 24 h later and as-
sessed for cytolytic activity and cell surface phenotype. Con-
trol or IL-152/2 mice injected with PBS exhibited low or
undetectable NK activity (Fig. 5 B). In contrast, both control
and IL-152/2 mice developed strong splenic NK activity af-
ter in vivo treatment with IL-15.
Both control and IL-152/2 mice responded to IL-15
treatment with similar increases (1.5–2-fold) in splenic cel-
lularity and similar phenotypic changes in splenic popula-
tions (Fig. 5 C, and data not shown). Both groups of IL-
15–treated mice had dramatic increases (.12-fold) in their
absolute numbers of splenic NK cells. In addition, the ab-
solute numbers of splenic NK T and CD81 T cells in-
creased by approximately three- to fivefold in both groups.
In contrast, the treatment had no effect on the absolute
numbers of splenic B or CD41 T cells (data not shown).
In vitro studies provide strong evidence that IL-15 is re-
quired for the later stages of NK cell maturation and ac-
quisition of cytolytic activity (37, 38). However, further
studies are needed to determine whether IL-15 reverses
the functional NK cell defect in IL-152/2 mice by ex-
panding and activating a severely reduced population of
mature NK cells and/or by driving the proliferation and
maturation of NK cell precursors.
IL-152/2 Mice Have a Reversible Defect in Memory Pheno-
type CD81 T Cells. Splenocytes and peripheral LN cells
were analyzed for cell surface expression of lymphoid and
myeloid cell surface markers (CD3e, CD4, CD8, CD11b,
CD19, CD45, Gr1, Ter119, and NK1.1). No dramatic
differences were noted in the relative proportions of B
cells, macrophages, granulocytes, or CD41 T cells be-
tween IL-152/2 and control mice (Table I, and data not
shown). In contrast, the relative proportions of splenic and
LN CD81 T cells were reduced approximately twofold in
IL-152/2 mice compared with their littermate controls
(Table I).
As noted above, treatment of IL-152/2 and control
mice with exogenous IL-15 increased the relative propor-
tion and absolute numbers of splenic CD81 T cells. This
observation is in accord with a previous study in which
Figure 5. IL-152/2 mice have a reversible NK cell defect. (A) In vitro lysis of 51Cr-labeled YAC-1 targets by splenocytes from IL-152/2 (triangles) or
littermate control (IL-151/1 or IL-151/2; squares) mice treated 24 h previously with PBS (open symbols) or 100 mg polyI:C (filled symbols). Data shown
are the mean 6 SEM for a total of five mice per group, analyzed in two experiments. The NK activity of splenocytes from IL-151/2 mice was indistin-
guishable from that of IL-151/1 mice. None of the splenocytes induced significant lysis of NK-resistant P815 targets (data not shown). (B) In vitro lysis
of YAC-1 targets by splenocytes from control (circles) or IL-152/2 (squares) mice treated with PBS (open symbols) or IL-15 (filled symbols). Groups of
two IL-152/2 or control (IL-151/1 or IL-151/2) mice were injected intraperitoneally with PBS or 10 mg human IL-15 once daily for 7 d. Spleens were
removed 24 h after the last injection. The responses of the individual mice in each group were similar, and the data are shown as the average response of
two mice per group. Significant lysis of P815 targets was observed only with splenocytes from IL-15–treated control mice and only at the highest E/T ra-
tio (30% lysis at E/T of 200:1; data not shown). The results shown are representative of two experiments. (C) Splenocytes from mice treated as described
in B were analyzed for cell surface expression of NK1.1 and CD3. The numbers shown represent the percentage of cells within each quadrant. The re-
sults are representative of four experiments. Data not shown: splenic cellularity was similar in PBS-treated control and IL-152/2 mice. IL-15 treatment
increased the splenic cellularity z1.5–2-fold in both groups of mice.777 Kennedy et al.
IL-15 was shown to be a selective T cell growth factor for
memory phenotype CD81 T cells in vitro and in vivo
(14). In that study, IL-15 induced strong in vitro prolifera-
tion of purified memory (CD44hi) phenotype CD81 T
cells but failed to stimulate proliferation of naive pheno-
type CD81 T cells or naive or memory phenotype CD41
T cells. In addition, injection of mice with IL-15 induced
selective turnover of the memory phenotype CD81 T cell
population. Thus, it was of interest to determine whether
the reduction in peripheral CD81 T cells in IL-152/2
mice preferentially affected the memory phenotype (CD44hi)
CD81 T cell population.
Three-color flow cytometry was used to analyze spleen
and LN cells for the expression of CD8, CD4, and CD44.
In IL-152/2 mice, there was a dramatic reduction in the
relative proportion of CD44hiCD81 cells in both the
spleen (Fig. 6 A) and LN (data not shown) compared with
the controls. The CD44hi population accounted for 19 6
2% of CD81 splenocytes and 14.2 6 2% of CD81 LN
cells in control mice but only 6.5 6 0.5% of CD81 sple-
nocytes and 2.8 6 0.2% of CD81 LN cells in IL-152/2
mice. In contrast, the relative proportion of CD44hi cells
within the CD41 population was similar in controls and
IL-152/2 mice in both spleen (22.2 6 2 vs. 22 6 1%, re-
spectively; Fig. 6 B) and LN (10.6 6 0.4 vs. 11 6 1%).
The normal numbers of thymic CD81 T cells but re-
duced numbers of memory phenotype CD81 T cells in
IL-152/2 mice suggest that IL-15 is not required for de-
velopment of CD81 T cells but is important for expansion
and/or maintenance of memory phenotype CD81 T cells
in the periphery. In this regard, short term treatment with
exogenous IL-15 induced dramatic increases in the relative
proportions and absolute numbers of memory phenotype
CD81 splenocytes and LN cells in both control and IL-
152/2 mice (Fig. 6, C and E, and Table II). In contrast,
IL-15 treatment had minimal effects on the relative pro-
portions or absolute numbers of memory phenotype
CD41 splenocytes and LN cells (Fig. 6, D and F, and Ta-
ble II). The ability of IL-15 to reverse the memory pheno-
type CD81 T cell defect in otherwise naive IL-152/2 mice
provides additional evidence to support a role for IL-15 in
expansion and/or maintenance rather than generation of
these cells. Future studies that track the fate of wild-type
memory phenotype CD81 T cells after transfer into IL-
152/2 hosts will likely clarify the relationship between IL-
15 and the memory phenotype CD81 T cell population.
IL-152/2 Mice Have Enhanced Susceptibility to Vaccinia Virus
Infection. IL-152/2 mice remained healthy when main-
tained under specific-pathogen free conditions. However,
given their severe defects in NK cell function and their se-
lective reduction in peripheral CD81 T cells, it was of in-
terest to determine whether these mice would be compro-
mised in their ability to respond to infectious agents.
Vaccinia virus was chosen for initial challenge studies, as
Table I. IL-152/2 Mice Have Reduced Levels of Peripheral 
CD81 T Cells
Percent 
B cells
Percent CD41
T cells
Percent CD81
T cells
CD4/CD8
ratio
Spleen
Control 39.0 6 2.4 19.8 6 0.4 10.4 6 0.5 2.1 6 0.1
IL-152/2 43.2 6 2.8 22.0 6 0.6 5.8 6 0.2 3.9 6 0.2
LN
Control 24.4 6 1.0 33.2 6 0.7 26.5 6 0.9 1.3 6 0.1
IL-152/2 30.9 6 0.8 40.4 6 0.8 14.4 6 0.4 2.8 6 0.1
Splenocytes and LN cells from IL-152/2 and controls (IL-151/1 and IL-
151/2) were analyzed by flow cytometry. Mice were between 9 and 15
wk of age and were sex- and age-matched in each experiment. The
subsets were defined as follows: CD191CD45R1 (B cells); CD31CD41
or CD41CD82 (CD4+ T cells), and CD31CD81 or CD42CD81
(CD81 T cells). Data represent the mean 6 SEM percentage of cell
populations from 11–24 mice, determined in 4–6 experiments.
Figure 6. IL-152/2 mice have a reversible defect in CD81 memory
phenotype (CD44hi) T cells. Splenocytes and LN cells were incubated
with mAb specific for CD4, CD8, and CD44. Gated populations of CD81
or CD41 cells were analyzed for expression of CD44. The CD44hi popu-
lations are indicated by the horizontal bars on each histogram. (A and B)
CD44 expression was analyzed on CD81 and CD41 splenocytes and LN
cells from individual 15-wk-old naive C57BL/6 (B6) or IL-152/2 female
mice (n 5 4/group). Similar patterns were observed in both LNs (not
shown) and spleen. (A) CD44 expression on CD81 splenocytes from con-
trol (solid line) or IL-152/2 (dashed line) mice. The mean percentage 6
SEM of CD44hi cells within the CD81 population was 19 6 2% for con-
trol mice and 6.5 6 0.5% for IL-152/2 mice. (B) CD44 expression on
CD41splenocytes from control (solid line; 22.2 6 2% CD44hi) or IL-152/2
(dashed line; 22 6 1% CD44hi) mice. (C–F) 9-wk-old C57BL/6 or IL-
152/2 female mice (n 5 3/group) were injected intraperitoneally with
PBS (dashed line) or 10 mg human IL-15 (solid line) once daily for 7 d.
Spleens and LNs were removed 24 h after the last injection. Single cell sus-
pensions from individual mice were analyzed for CD4, CD8, and CD44
expression as described above. Similar changes were observed in both LNs
(not shown) and spleen (see Table II for summary of data). (C and E)
CD44 expression on CD81 splenocytes from PBS- or IL-15–treated con-
trol (C) or IL-152/2 (E) mice. (D and F) CD44 expression on CD41 sple-
nocytes from PBS- or IL-15–treated control (D) or IL-152/2 (F) mice.778 IL-15–deficient Mice
both NK cell and CD81 T cell responses are crucial for
mounting protective responses to this virus (39–41). IL-152/2
and C57BL/6 female mice (n 5 8/group) were infected with
the virulent neurotropic strain of vaccinia virus and assessed
daily for morbidity and mortality. By day 4 after infection,
the IL-152/2 mice showed severe signs of virus-induced
morbidity (ruffled fur, hunched appearance, reduced activity,
and overt signs of cachectic fever), whereas the control mice
showed less severe clinical symptoms (data not shown). The
IL-152/2 mice were unable to resolve the infection and died
by day 9 after infection (Fig. 7). In contrast, only one of the
control mice died during this time period. The remaining
seven control mice cleared the infection and showed no signs
of morbidity by day 28 after infection. Thus, IL-15 is essential
for the host response to vaccinia virus.
Phenotypic Differences between IL-152/2 and IL-15Ra2/2
Mice. Recently, Lodolce et al. reported on the genera-
tion and characterization of IL-15Ra2/2 mice (20). The
phenotypes of IL-15Ra2/2 and IL-152/2 mice appear
similar in terms of their NK, NK T, IEL, and peripheral
CD81 T cell defects. The observation that the defects in
IL-152/2 mice are not more severe than those observed in
IL-15Ra2/2 mice suggests that the high-affinity IL-15R is
required for normal physiological responses to IL-15.
Interestingly, the phenotypes that are observed in IL-
152/2 and IL-15Ra2/2 mice are not identical. IL-152/2
mice, like IL-2Rb2/2 mice (8, 42), appear to have normal
CD41 and CD81 thymic T cell development (Fig. 3). In
contrast, IL-15Ra2/2 mice may have impaired develop-
ment of CD81 T cells, as young mice exhibit an increased
ratio of single positive CD41 to CD81 thymocytes and a
slight thymic hypocellularity (25% decrease relative to
controls). In addition, IL-15Ra2/2 mice are markedly
lymphopenic (30–80% decreased cellularity compared
with controls), whereas IL-152/2 mice exhibited only a
slight degree of lymphopenia (15% decrease in average
weight and 29% decrease in average cellularity of LNs rel-
ative to controls; Fig. 2, B and D). Elucidation of the
mechanism(s) behind these phenotypic differences will re-
quire a systematic comparison of IL-152/2 and IL-15Ra2/2
mice that are of matched genetic backgrounds and housed
under identical conditions.
IL-152/2 mice will likely prove useful for defining the
role of IL-15 (and/or IL-15–dependent cell populations)
in host defense mechanisms against various pathogens, tu-
mors, and allografts. In particular, the ability to rescue the
NK and memory phenotype CD81 T cell defects in IL-
152/2 mice provides an ideal means by which to further
dissect the in vivo relationship between IL-15 and these
cell populations. When used in conjunction with appro-
priate animal models of disease, these mice should also
prove useful for determining whether dysregulated expres-
sion of IL-15 contributes to the pathogenesis of acute or
chronic autoimmune and inflammatory diseases.
We thank Randy Hall, Kathy Rohrbach, Kim Harrington, Eileen
Roux, Brenda Balogh, Steve Braddy, and Daniel Hirschstein for
technical assistance, Dana Schack for animal husbandry, Drs. Ken-
dall Mohler and Hilary McKenna for critical review of the manu-
script, Dr. Michael Butine for assistance with statistical analyses,
Gary Carlton for graphics, and Anne Aumell for assistance with the
manuscript.
Funding for S. Joyce was provided by National Institutes of
Health grant AI42284 and by the Juvenile Diabetes Foundation In-
ternational, NY.
Submitted: 5 November 1999
Revised: 22 December 1999
Accepted: 23 December 1999
Released online: 28 February 2000
Table II. In Vivo Treatment with IL-15 Expands Memory 
Phenotype CD44hiCD81 T Cells in Normal and IL-152/2 Mice
Percent CD44hi cells
within CD8 gate
Percent CD44hi cells
within CD4 gate
PBS IL-15 PBS IL-15
Splenocytes
C57BL/6 19.7 6 1.3 75.9 6 2.1 21.3 6 0.3 28.8 6 1.2
IL-152/2 9.5 6 0.5 45.6 6 4.8 20.2 6 1.1 27.1 6 1.7
LN cells
C57BL/6 12.4 6 0.4 55.5 6 1.4 11.5 6 1.2 13.4 6 0.4
IL-152/2 3.4 6 0.1 31.2 6 2.8 9.3 6 0.6 14.1 6 0.8
9-wk-old C57BL/6 or IL-152/2 female mice (n = 3/group) were injected
intraperitoneally with PBS or 10 mg human IL-15 once daily for 7 d.
Spleens and LNs were removed 24 h after the last injection. Single cell
suspensions of spleen and LN cells from individual mice were incubated
with mAb specific for CD4, CD8, and CD44. Gated populations of
CD81 or CD41 cells were analyzed for expression of CD44. Results are
expressed as the mean 6 SEM percentage of CD44hi cells within the gated
CD81 or CD41 populations. Data not shown: IL-15 treatment had
minimal effects on the absolute number of CD41 cells but increased the
absolute number of CD81 cells in spleen and LNs by two- to threefold in
C57BL/6 mice and three- to fivefold in IL-152/2 mice.
Figure 7. Susceptibility of IL-152/2 mice to infection with vaccinia vi-
rus. Groups of eight female C57BL/6 or IL-152/2 mice were inoculated
intravenously with 106 PFU of vaccinia virus. Mice were monitored daily
for morbidity (data not shown) and mortality. Data shown are representa-
tive of two experiments.779 Kennedy et al.
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